Close
Almac
Achema middle east

New Zealand Health Groups Strive To Enhance Clinical Trials

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

Based on recommendations from an independent study report titled Enhancing Aotearoa New Zealand Clinical Trials, New Zealand’s top health agencies will examine system-level adjustments to enhance the benefits from clinical trials.

The report was created by a broad team of clinical researchers, advisory groups, and consumer groups and was funded by the Ministry of Health and the Health Research Council of New Zealand (HRC). The study outlines important elements of a flourishing health research sector and the priorities of the New Zealand Health Research Approach in an effort to strengthen the environment for clinical trials.

Several recommendations are made in the report for improving access to and participation in clinical trials, with an emphasis on lowering disparities and carrying out studies that are pertinent to Aotearoa New Zealand.

A new model for assisting clinical trials is also put forth, one that includes a national centre to provide direction, oversight, knowledge, and high-level collaboration on trial activity, as well as numerous regional coordinating centres to assist trials locally.

A senior cross-agency working group will be formed by Health New Zealand and the Mori Health Authority in response to the study to investigate how the recommendations may be incorporated into the healthcare system. Each organisation will designate a lead for the project.

According to Dr. Ian Town, the Ministry of Health’s main science advisor, the health sector changes offer a structural foundation for a more intelligent and equitable health system, and this presents a chance to greatly improve clinical research in the public health system.

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »